Qiagen has entered into an agreement with Lepu Medical Technology to provide its ESEQuant lateral flow system for use in emergency rooms with Lepu's tests for cardiac markers that diagnose acute myocardial infarction.

Based on receiving China’s State Food and Drug Administration approval, Lepu will market the system in China under the name LEPU Quant-Gold.

Qiagen global strategic alliances and OEM head Frank Krieg-Schneider said the company is meeting a pressing need for heart patients by combining ESEQuant’s quick turnaround time with the reliability of Lepu’s tests for cardiac biomarkers.

"This agreement advances two strategic initiatives: First, our geographic presence is further broadened by the addition of important point of need assays in China," Krieg-Schneider added.

"Secondly, we are driving platform success by launching ESEQuant as an SFDA-approved device in a lifesaving medical application, a milestone for our emerging Point of Need portfolio."